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Policy-makers throughout Europe and beyond have been
working to develop and implement, and further adjust, the
most appropriate mix of policy measures in pharmaceuti-
cal pricing and reimbursement to ensure equitable access
to medicines despite limited budgets. The experience with
policies in other countries is highly valuable information
for them.
In order to support policy-makers, the Pharmaceutical
Pricing and Reimbursement Information (PPRI) network
of competent authorities was established in 2005, with
the aim to offer a platform for competent authorities of
pharmaceutical pricing and reimbursement to exchange
information and data and to establish a sustainable
reporting system for country information.
Within the decade of PPRI’s existence, more than 60
country reports (information about medicines policies for
the out-patient sector, hospital pharma reports, and inte-
grated country profiles about the out-patient and the in-
patient sectors) of 28 different countries and more than 60
country posters were produced. Comparative analyses
were undertaken, e.g. in the PPRI report [1], the PHIS
Hospital Pharma report [2] or in scientific articles [3-5].
A glossary [6] and indicators were developed and are regu-
larly updated. These deliverables have been shared in the
open domain (http://whocc.goeg.at/Publications/).
In addition to these reports and tools, the instrument of
PPRI network queries has proven its importance. A PPRI
network query allows PPRI network members to ask for
specific and quick information about a policy and situation
in the other countries represented in the PPRI network [7].
In total, 319 PPRI queries have been launched until
June 2015.
The PPRI network is predominantly Europe-based. It
has been growing over the years and currently comprises
competent authorities for pharmaceutical pricing and
reimbursement from 45 countries (thereof all 28 European
Union Member States, another twelve European countries,
and five non-European countries) as well as European and
international institutions (European Commission, OECD,
WHO, World Bank). Face-to-face meetings of the PPRI
network are organised twice a year. The PPRI network is
characterized by trust and mutual respect.
The last decade has brought both new challenges (e.g.
financial constraints due to the crisis, new premium-priced
medicines) and opportunities (e.g. new policy tools such as
managed-entry agreements, patent expiries of biotechnolo-
gical medicines) for policy-makers. Participation in the
PPRI network has supported them to deal with these
developments and discuss possible solutions and colla-
borative approaches. In the light of on-going challenges,
the PPRI network is well placed and prepared to continue
playing its role as discussion and information exchange
platform for the years to come.
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